An observational study in Acute Myeloid Leukemia, sponsored by AbbVie. Recruiting at 8 sites in Colombia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by AbbVie · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Leukemia, Myeloid, Acute by AbbVie — 4 open to participants now, 10 under way, 3 of them phase 3. Leukemia, Myeloid, Acute · AbbVie.
Among the 43 studies in Leukemia, Myeloid, Acute by AbbVie, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2023, is one of 10 observational ones, and was the 36th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →4 of the 43 studies in Leukemia, Myeloid, Acute by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Austria, France and 4 more countries
Ages 18+
AbbVie · Sites in United States, Australia, France and 4 more countries
Ages 6 mo–17 yrs
AbbVie · Sites in India
Ages 18+
By country, each count listing its studies:
Of the 621 Leukemia, Myeloid, Acute studies recruiting now, 361 (58%) set no upper age limit and 220 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 7 · Phase 3 8 · Phase 4 2
First in 2010; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is below the median of 114 across 395 observational studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 62 across the 32 interventional studies, 113 across the 10 observational. Of the 31 that completed or were terminated, 7 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
5 of the studies in Leukemia, Myeloid, Acute by AbbVie that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT05587049AbbVieA Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia | 2026-11 |
| NCT04086264AbbVieIMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | 2027-02 |
| NCT03987958AbbVieA Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study) | 2027-07 |
| NCT07044687AbbVieStudy to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 43 studies in Leukemia, Myeloid, Acute by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well venetoclax in combination with azacitidine works to treat AML in adult participants in Colombia.
Venetoclax in combination with azacytidine is approved to treat Acute myeloid leukemia (AML). All study participants will receive venetoclax in combination with azacitidine as prescribed by their study doctor in accordance with approved local label. Adult participants with a new diagnosis of AML will be enrolled. Around 70 participants will be enrolled in the study in Colombia.
Participants will receive venetoclax tablets to be taken by mouth in combination with azacitidine given by subcutaneous (SC) or intravenous (IV) injection according to the approved local label. The duration of the study is approximately 36 months.
There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice.
Newly diagnosed AML participants who are ineligible to intensive chemotherapy, that starting treatment with Venetoclax in combination with azacytidine treated according to the Colombia label.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Participating in an interventional clinical trial within 30 days prior to Venetoclax treatment initiation.
Participants treated with venetoclax in combination with azacitidine in accordance with approved local label.
Overall Survival (OS)
OS defined as the time from the date of start Venetoclax to the date of death from any cause.
Time frame: Up to 18 months
Percentage of Participants Achieving Complete Remission (CR)
CR is defined according to the modified International Working Group (IWG) criteria for acute myeloid leukemia (AML) as no morphologic evidence of AML and absolute neutrophil count \>=10\^3 /μL (\>=1.0 x 10\^9 /L), platelets \>=10\^5 /μL (\>=100 x 10\^9 /L), red blood cell (RBC) transfusion independence, and bone marrow with \<5% blasts. Absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease.
Time frame: Up to 18 Months
Percentage of Participants Achieving Complete Remission with Incomplete Marrow Recovery (Cri)
Cri is defined according to the modified IWG criteria for AML as all criteria as CR except for residual neutropenia \<10\^3 /μL (1,000/ μL), or thrombocytopenia \<10\^5 /μL (100,000/ μL). If all criteria for CR are meet except for RBC transfusion independence, this also fulfills Cri criteria.
Time frame: Up to 18 Months
Percentage of Participants Achieving Complete Remission with Incomplete Marrow Recovery (CRh)
CRh is defined according to the modified IWG criteria for AML as bone marrow with \< 5% blasts and Peripheral blood neutrophil count of \> 0.5 × 10\^3 /μL and Peripheral blood platelet count of \> 0.5 × 10\^5 /μL and 1-week (\>= 7 days) platelet transfusion-free period prior to the hematology lab collection.
Time frame: Up to 18 Months
Percentage of Participants Achieving Transfusion Independence
Transfusion ndependence is defined as a period of at least 56 days with no transfusion between the first dose of Venetoclax and the last dose of Venetoclax plus 30 days.
Time frame: Up to 18 Months
Event-Free Survival (EFS)
EFS defined as the time from the date of start Venetoclax to the date of morphologic relapse, progressive disease, resistant disease, treatment failure, or death from any cause.
Time frame: Up to 18 Months
Duration of Remission (DOR)
DOR defined as the time from the date of first CR, CRi or CRh to the earliest evidence of morphologic relapse, progressive disease, or death due to disease progression.
Time frame: Up to 18 Months
Duration of Treatment (DoT)
DoT defined as the time from the start of a therapy to the time of treatment discontinuation for any reason.
Time frame: Up to 18 Months
Percentage of participants with Adverse Events (AE)
AE, defined as any unfavorable medical event that is temporarily related to the use of the investigational product, which does not necessarily have a causal relationship with the investigational product.
Time frame: Up to 18 Months
Percentage of participants achieving Minimal Residual Disease (MRD) negativity
MRD negativity, defined as having less than 10\^-3 residual blasts per leukocyte measured in the bone marrow.
Time frame: Up to 18 Months
Change in Health-Related Quality of Life (HRQOL) Score
HRQOL score, defined as a multidimensional construct defined as the subjective perception of the life as a whole, including physical, emotional, social, cognitive functions, disease symptoms and side effects of treatment.
Time frame: Up to 18 Months
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: Undecided
Started Nov 2023 (actual). Primary completion is estimated for Nov 2026, 36 months after the start.
Of 160 observational studies under Leukemia, Myeloid, Acute, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 154. This study's planned 36 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.